ABTL0812 (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "ABTL0812" in English language version.

refsWebsite

Global rank English rank

1prnewswire.com

406^th place

258^th place

low place

7,595^th place

1medicalxpress.com

8,255^th place

low place

2^nd place

2^nd place

102^nd place

76^th place

4^th place

4^th place

biospace.com

"Ability Pharmaceuticals Announces Positive Phase 1 1b Study Results Of ABTL0812 In Cancer Patients With Advanced Solid Tumors". www.biospace.com.

doi.org

Erazo T, Lorente M, López-Plana A, Muñoz-Guardiola P, Fernández-Nogueira P, García-Martínez JA, et al. (May 2016). "The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase". Clinical Cancer Research. 22 (10): 2508–19. doi:10.1158/1078-0432.ccr-15-1808. hdl:2445/207600. PMID 26671995.

handle.net

hdl.handle.net

Erazo T, Lorente M, López-Plana A, Muñoz-Guardiola P, Fernández-Nogueira P, García-Martínez JA, et al. (May 2016). "The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase". Clinical Cancer Research. 22 (10): 2508–19. doi:10.1158/1078-0432.ccr-15-1808. hdl:2445/207600. PMID 26671995.

medicalxpress.com

"New mechanism of antitumor action identified". Medical Xpress. 25 January 2016.

nih.gov

pubmed.ncbi.nlm.nih.gov

Erazo T, Lorente M, López-Plana A, Muñoz-Guardiola P, Fernández-Nogueira P, García-Martínez JA, et al. (May 2016). "The New Antitumor Drug ABTL0812 Inhibits the Akt/mTORC1 Axis by Upregulating Tribbles-3 Pseudokinase". Clinical Cancer Research. 22 (10): 2508–19. doi:10.1158/1078-0432.ccr-15-1808. hdl:2445/207600. PMID 26671995.

prnewswire.com

"Ability Pharmaceuticals Announces Orphan Drug Designation in the US for ABTL0812 in Pancreatic Cancer". Ability Pharmaceuticals SL.